Incyte Corp. Receives a Buy from J.P. Morgan

By Ryan Adsit

J.P. Morgan analyst Cory Kasimov reiterated a Buy rating on Incyte Corp. (NASDAQ: INCY) on November 1 and set a price target of $101. The company’s shares closed yesterday at $87.19.

According to TipRanks.com, Kasimov is ranked 0 out of 5 stars with an average return of -15.7% and a 23.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Karyopharm Therapeutics, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Incyte Corp. is Strong Buy and the average price target is $106.75, representing a 22.4% upside.

In a report issued on October 24, RBC Capital also maintained a Buy rating on the stock with a $113 price target.

Incyte Corp.’s market cap is currently $16.38B and has a P/E ratio of 111.78. The company has a book value ratio of 55.1368.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year. Most recently, in February 2016, Yao Wenqing, the EVP, Discovery Medicinal and P of INCY bought 6,566 shares for a total of $120,289.

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.